Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 20:12:31时区推断·⟳ 抓取 20:13:24·⚡ 决策 07-30 20:15:56 +2m32s·89.2 天前
Nuwellis儿科Aquadex疗法抗凝用药回顾性研究获期刊接收
该事件只是单中心回顾性可行性研究获刊接收，研究本身明确不是优效性证明，也不是监管批准、适应症扩展、订单或报销变化。
📄 原文Investing.com↗ 原文
Nuwellis study shows epoprostenol use in pediatric therapy
U.S. launches fresh strikes on Iran as fighting intensifies across Middle East MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUW…
不做 Nuwellis（NUWE.US）
单中心回顾性研究获刊接收，且作者称只是可行性报告；没有监管获批、订单、报销或可量化商业增量，事件对标的太小，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 low · price-in 风险 low ↗
关键理由
- 该事件只是单中心回顾性可行性研究获刊接收，研究本身明确不是优效性证明，也不是监管批准、适应症扩展、订单或报销变化。
- Aquadex系统已可用于20公斤及以上成人和儿科患者，本次信息未改变产品准入边界或可量化商业化空间。
主要风险
- 若后续出现多中心临床、指南采纳、医院采购或监管标签变化，需要按新事件重新评估。
原文全文
展开原文 · 2,140 字
U.S. launches fresh strikes on Iran as fighting intensifies across Middle East
MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE) announced today that a single-center retrospective study has been accepted for publication in Frontiers in Pediatrics examining the use of epoprostenol as an anticoagulant during Aquadex therapy in critically ill pediatric patients.
The study, titled "Epoprostenol as an Alternative Anticoagulant for Pediatric Aquadex Therapy: A Safe and Feasible Option," reviewed 46 children representing 52 treatment courses at UPMC Children’s Hospital of Pittsburgh from September 2022 to September 2025. The research documented the first use of epoprostenol as the sole anticoagulant for children undergoing Aquadex ultrafiltration therapy in intensive care units.
According to the study findings, filters lasted a median of approximately two days, platelet counts remained steady or increased modestly, and no bleeding events were attributed to the drug. The need for vasoactive support did not increase during treatment.
"For our sickest children, the usual ways of keeping these circuits open aren’t always good options. This study suggests epoprostenol could give us another tool at the bedside, one that doesn’t add to bleeding risk or require intensive metabolic monitoring," said Dana Y. Fuhrman, DO, MS, the study’s senior author.
The authors characterized the findings as a feasibility report rather than proof of superiority over conventional anticoagulation methods. Epoprostenol is a short-acting drug that prevents platelet clumping and has a short half-life, meaning its effect diminishes quickly when therapy stops.
The Aquadex SmartFlow System is indicated for continuous ultrafiltration therapy in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics.
Nuwellis provided financial support to underwrite the cost of open access publication but did not fund the research itself, according to a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE) announced today that a single-center retrospective study has been accepted for publication in Frontiers in Pediatrics examining the use of epoprostenol as an anticoagulant during Aquadex therapy in critically ill pediatric patients.
The study, titled "Epoprostenol as an Alternative Anticoagulant for Pediatric Aquadex Therapy: A Safe and Feasible Option," reviewed 46 children representing 52 treatment courses at UPMC Children’s Hospital of Pittsburgh from September 2022 to September 2025. The research documented the first use of epoprostenol as the sole anticoagulant for children undergoing Aquadex ultrafiltration therapy in intensive care units.
According to the study findings, filters lasted a median of approximately two days, platelet counts remained steady or increased modestly, and no bleeding events were attributed to the drug. The need for vasoactive support did not increase during treatment.
"For our sickest children, the usual ways of keeping these circuits open aren’t always good options. This study suggests epoprostenol could give us another tool at the bedside, one that doesn’t add to bleeding risk or require intensive metabolic monitoring," said Dana Y. Fuhrman, DO, MS, the study’s senior author.
The authors characterized the findings as a feasibility report rather than proof of superiority over conventional anticoagulation methods. Epoprostenol is a short-acting drug that prevents platelet clumping and has a short half-life, meaning its effect diminishes quickly when therapy stops.
The Aquadex SmartFlow System is indicated for continuous ultrafiltration therapy in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics.
Nuwellis provided financial support to underwrite the cost of open access publication but did not fund the research itself, according to a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。